Product/Composition:- | Tetracycline tablets/Capsules |
---|---|
Strength:- | 250 mg, 500 mg |
Form:- | Tablet/Capsules |
Reference Brands:- | Sumycin(US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA attachment. It effectively treats respiratory, urinary, and skin infections. Benefits include broad-spectrum activity, rapid bacterial eradication, and oral administration, making it a reliable option for managing various bacterial infections.
Tetracycline tablets are approved in the EU and US for respiratory, urinary, and skin bacterial infections. In the EU, brands like Sumycin are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generic formulations are available. Both regions require detailed dossiers, including clinical trial results, manufacturing practices, and pharmacovigilance plans for approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access for tetracycline, ensuring adherence to European and US standards for safe, effective antimicrobial therapy.